Overcoming Barriers to a Global Treaty on Medical Funding and R&D

Journal of the Brazilian Institute for Intellectual Property (7): 70-76

7 Pages Posted: 19 Jan 2013 Last revised: 2 May 2015

Ryan Abbott

University of Surrey School of Law; University of California, Los Angeles - David Geffen School of Medicine

Date Written: December 1, 2012

Abstract

It has long been recognized that the developing world needs better and more accessible medicines. However, ensuring that medicines now widely available in the developed world are delivered at affordable prices, and incentivizing R&D for diseases that primarily affect the world’s poor, has proven a stubborn challenge. Most recently, a 2012 World Health Organization sponsored report has proposed negotiation on a global treaty that would commit Member States to spend at least 0.01% of their gross domestic product on R&D that addresses the special health needs of developing countries, and that would require at least 20% of this funding to be spent through a single pooled financing mechanism. This article analyzes the key components of the WHO proposal and their potential impact on public health. It proposes strategies to convert parties currently opposing the treaty, and argues that a limited market-exclusivity regime has the capacity for a meaningful impact.

Keywords: medical financing, drug development, neglected diseases, World Health Organization

Suggested Citation

Abbott, Ryan, Overcoming Barriers to a Global Treaty on Medical Funding and R&D (December 1, 2012). Journal of the Brazilian Institute for Intellectual Property (7): 70-76. Available at SSRN: https://ssrn.com/abstract=2203550

Ryan Benjamin Abbott (Contact Author)

University of Surrey School of Law ( email )

Guildford
Guildford, Surrey GU2 5XH
United Kingdom

University of California, Los Angeles - David Geffen School of Medicine ( email )

1000 Veteran Avenue, Box 956939
Los Angeles, CA 90095-6939
United States

Paper statistics

Downloads
77
Rank
259,993
Abstract Views
623